文献速递泌尿生殖技术与安全PETCT

18F-DCFPyL PET/CT对复发性前列腺癌患者管理的影响:前瞻性多中心注册试验结果

Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial.
PubMed 文献 · Radiology · 2022-01-25

这项前瞻性多中心注册试验纳入1289例生化失败后怀疑低体积复发的前列腺癌男性,评估18F-DCFPyL PSMA PET/CT的检出率及对管理的影响。PSMA PET在65%的患者中检出病灶,58%的患者管理计划发生改变,20%由姑息转为治愈性意图。

要点

  • PSMA PET在65%(841/1289)的生化失败患者中检出病灶,常规影像阴性者中检出率为62%(615/999)。
  • PSA<0.5 ng/mL、0.5-1.0 ng/mL、>1.0 ng/mL的检出率分别为38%、63%、83%。
  • 58%(748/1289)的患者PET后管理计划改变,20%(255/1289)由姑息转为治愈性意图。

核心结论

  • PSMA PET在约60%的生化失败且怀疑低体积转移的患者中较常规影像检出额外病灶,导致频繁的管理改变,包括20%由姑息转为治愈或根治意图。

研究设计与样本

  • 前瞻性多中心注册试验(PREP,NCT03718260),纳入1289例生化失败后常规影像(CT和骨扫描)显示0-4个病灶的男性,中位年龄71岁(IQR 65-75岁)。

关键影像表现/征象

  • PSMA PET在841/1289(65%)的患者中检出病灶,在常规影像阴性的999例中检出615例(62%)。
  • 31%(399/1289)为局部区域复发,24%(314/1289)为寡转移,10%(128/1289)为广泛转移。

诊断标准与关键数值

  • PSA<0.5 ng/mL组检出率38%(160/424),PSA 0.5-1.0 ng/mL组63%(107/171),PSA>1.0 ng/mL组83%(573/692)。
  • PET后管理计划改变见于748/1289(58%),管理意图改变见于371/1250(30%),其中由姑息转为潜在治愈意图255/1289(20%)。

局限性

  • 原文指出需要长期随访以确定管理改变是否影响疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The high positivity rate of prostate-specific membrane antigen (PSMA) PET in the setting of biochemical failure (BCF), even when conventional imaging is negative, is promising. Purpose To assess the disease detection rate of PSMA-based PET/CT with fluorine 18-DCFPyL as a radiotracer and the PET-directed management change in men with suspected limited recurrent prostate cancer. Materials and Methods This prospective multicenter registry (Ontario PSMA-PET Registry for Recurrent Prostate Cancer, or PREP) enrolled men with BCF after primary therapy (radical prostatectomy plus or minus salvage radiation therapy or primary radiation therapy) and zero to four disease sites at conventional imaging (CT and bone scintigraphy). The positivity rate of PSMA PET according to serum prostate-specific antigen (PSA) level; frequency of local-egional, oligometastatic, and extensive metastatic recurrence; and rate of change in management after PET findings were recorded. The nonparametric Mood median test was used to assess the association between serum PSA level and change in management. Results A total of 1289 men (median age, 71 years [interquartile range, 65-75 years]) were evaluated. PSMA PET helped detect disease in 841 of 1289 men (65%) and in 615 of 999 men (62%) with negative conventional imaging. The recurrence detection rates according to serum PSA level at enrollment were 38% (160 of 424 men), 63% (107 of 171 men), and 83% (573 of 692 men) for PSA under 0.5 ng/mL, 0.5-1.0 ng/mL, and above 1.0 ng/mL, respectively. At PSMA PET, 399 of 1289 men (31%) had local-regional recurrence, 314 (24%) had oligometastatic disease, and 128 (10%) had extensive metastases. Following PET examination, a change in planned management was recorded in 748 of 1289 men (58%), and in 371 of 1250 men (30%), there was a change in management intent, more commonly from palliative to potentially curative intent (255 of 1289 men [20%]). Conclusion Prostate-specific membrane antigen PET helped detect additional sites of disease compared with conventional imaging in approximately 60% of men with biochemical failure and suspected low-volume metastatic disease, resulting in frequent change in management, including a change from palliative to curative or radical intent therapy in 20% of men. Long-term follow-up is needed to determine whether this impacts disease control. Clinical trial registration no. NCT03718260 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Civelek in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Metser, Zukotynski, Mak, et al. Effect of 18F-DCFPyL PET/CT on the Management of Patients with Recurrent Prostate Cancer: Results of a Prospective Multicenter Registry Trial. Radiology. 2022. PMID: 35076300. doi:10.1148/radiol.211824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。